Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 42

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 42
---
 choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could
occur, the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or
result in downward pressure on the price of our common stock, and our ability to raise capital in the future.

Holders of our warrants and pre-funded warrants will have no rights as a common stockholder until they acquire our common stock.

Until you acquire shares of
our common stock upon exercise of your warrants or pre-funded warrants, you will have no rights with respect to shares of our common stock
issuable upon exercise of your warrants or pre-funded warrants. Upon exercise of your warrants or pre-funded warrants, you will be entitled
to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.

The warrants may not have any value.

Each warrant will have an
exercise price of not less than 100% of the last reported sale price of our common stock as of the close of the trading day immediately
preceding the pricing of this offering and will expire on the [_] anniversary of the date they first become exercisable. In the event
our common stock price does not exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants
may not have any value.

There is no public market for the warrants to purchase shares of our common stock or pre-funded warrants being offered in this offering.

There is no established public
trading market for the warrants or pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition,
we do not intend to apply to list the warrants or pre-funded warrants on any national securities exchange or other nationally recognized
trading system, including The Nasdaq Capital Market. Without an active trading market, the liquidity of the warrants and pre-funded warrants
will be limited.

| 21 |

We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.

Each
Pre-Funded Warrant will be exercisable until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise.
Accordingly, we will not receive any meaningful additional funds upon the exercise of the Pre-Funded Warrants.

Significant holders or beneficial holders of shares of